跳至主要内容
临床试验/2023-508184-74-00
2023-508184-74-00已完成1 期

A trial to determine how nanatinostat is absorbed, modified, and removed from the body and the amount of nanatinostat that becomes available to the body in patients with cancers that is very large or has spread to other parts of the body

Viracta Therapeutics Inc., Viracta Therapeutics Inc.1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2024年2月12日最近更新:

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
20
试验地点
1
A trial to determine how nanatinostat is absorbed,... | 临床试验